Sri Lanka

The primary regulatory authority for health products in Sri Lanka is the National Medicines Regulatory Authority (NMRA), established under the National Medicines Regulatory Authority Act No. 5 of 2015. The NMRA oversees the registration and market authorization of pharmaceuticals, medical devices, diagnostics, and related health products. All health products intended for sale or distribution in Sri Lanka must be registered with the NMRA prior to market entry. The approval process involves submission of a dossier, technical evaluation by the relevant expert committee, and issuance of a registration certificate. Medical devices are classified according to risk-based categories, and the NMRA has progressively aligned its device regulatory framework with international standards, including IMDRF guidelines. Digital health products and software as a medical device (SaMD) fall under emerging review pathways that are still being formalized.

Applications to the NMRA must be submitted through a locally registered entity, as a licensed local agent or representative is mandatory for all foreign manufacturers. Pharmaceutical dossiers are generally accepted in the ACTD (ASEAN Common Technical Document) format, although CTD-formatted submissions are also recognized and increasingly preferred for alignment with international norms. Supporting documentation typically includes proof of registration in a reference country, GMP certification from the manufacturer, product specifications, clinical and safety data, and labeling compliant with Sri Lankan requirements. In recent years, the NMRA has introduced reforms aimed at reducing registration backlogs and accelerating approvals for priority medicines, including a fast-track pathway for products already approved by stringent regulatory authorities (SRAs) such as the US FDA, EMA, TGA, and Health Canada. The NMRA is also working toward greater digital integration of its submission and tracking systems to improve transparency and efficiency.

Public sector procurement of health products in Sri Lanka is centrally coordinated through the Ministry of Health (MoH) in collaboration with the State Pharmaceuticals Corporation (SPC) and the State Pharmaceuticals Manufacturing Corporation (SPMC). The SPC serves as the principal procurement and distribution agency for medicines and medical supplies for public health facilities, operating through a national tender system managed by the Procurement Committee of the MoH. Tenders are typically issued annually for essential medicines and medical devices listed on the national essential medicines list (NEML), and suppliers must hold a valid NMRA registration to participate. The procurement framework is governed by the National Procurement Guidelines issued by the Ministry of Finance, and all major public tenders above specified thresholds are subject to oversight by the National Procurement Commission. Sri Lanka operates a largely centralized procurement model, with provincial health authorities having limited independent procurement authority for smaller or locally needed items.

The private sector represents a significant and growing channel for health product sales in Sri Lanka, with a network of private hospitals, pharmacies, and diagnostic laboratories sourcing products independently from registered importers and distributors. Multinational companies and local agents often serve both public and private channels simultaneously. Sri Lanka also benefits from donor-funded procurement through international agencies including UNICEF, the Global Fund (for HIV, tuberculosis, and malaria programs), and WHO, which support the public health system with supplementary supplies, particularly for communicable disease control and maternal and child health programs. USAID and bilateral development partners have historically contributed to health commodity supply in targeted program areas. The government maintains a stated preference for locally manufactured products and has incentivized domestic production through the SPMC and favorable tender evaluation criteria for locally produced generics, as part of broader import substitution and health security policy objectives.